Search Results - jian-kang+jiang

4 Results

Sort By:

Anti-Viral Compounds that Inhibit HIV Activity

Abstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity. Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses...

Published: 4/8/2024 | Inventor(s): John Beutler, Jian-kang Jiang, Suhman Chung, Craig Thomas, Stuart LeGrice, Jennifer Wilson

Keywords(s): AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic...

Published: 10/28/2024 | Inventor(s): Jian-kang Jiang, Khalida Shamim, Philip Sanderson, Wei Zheng, Xiuli Huang, Gregory Tawa, Asaf Alimardanov, Arthur Lee, Junfeng Huang, Wenwei Huang

Keywords(s): ALK2, BMP, INHIBITING, Inhibitors, Methods, Novel, SIGNALING, VGXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Endocrinology, Application > Therapeutics, Application > Research Materials

Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance

This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...

Published: 10/28/2024 | Inventor(s): Jian-kang Jiang, Craig Thomas

Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...

Published: 11/5/2024 | Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas

Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials